HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allogeneic marrow transplantation for acute lymphoblastic leukemia in remission using fractionated total body irradiation.

Abstract
Twelve patients with acute lymphoblastic leukemia in second to fourth remission received allogeneic marrow transplants following preparation with cyclophosphamide, 120 mg/kg and 1400 rad of fractionated total body irradiation. Two patients died of interstitial pneumonitis 32 and 62 days post-transplantation. Six patients relapsed between days 59 and 659 and four died of leukemia-related problems. Two patients who relapsed are currently alive, one in remission and one in relapse. Four patients are alive and free of disease 657 to 991 days following transplantation. This disease-free survival was not significantly better than the six of 22 disease-free survivors previously observed following cyclophosphamide and 1000 rad of total body irradiation given in a single exposure.
AuthorsR A Clift, C D Buckner, E D Thomas, J E Sanders, P S Stewart, R McGuffin, J Hersman, K M Sullivan, G E Sale, R Storb
JournalLeukemia research (Leuk Res) Vol. 6 Issue 3 Pg. 409-12 ( 1982) ISSN: 0145-2126 [Print] England
PMID6750254 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Topics
  • Adolescent
  • Adult
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Graft vs Host Reaction
  • Humans
  • Leukemia, Lymphoid (radiotherapy, therapy)
  • Probability
  • Prognosis
  • Recurrence
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: